Genome Profiling, LLC ("GenPro")

Discovering and translating novel epigenetic biomarkers into high-throughput low-cost precision assays for patient stratification and early disease detection

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Newark, DE, US
  • Currency USD
  • Founded June 2014
  • Employees 5
  • Incorporation Type LLC
  • Website

Company Summary

GenPro is a molecular information company specializing in novel epigenetic biomarker (EpiMarkerTM) discovery from next generation sequencing data and the translation of EpiMarkers into high-throughput / low cost precision qPCR assays for patient stratification, early disease detection, companion diagnostics, diagnostics and new insights into genes, pathways, mechanisms of actions and new epigenetic targets across many diseases.


  • Chairman, CEO and Co-Founder With more than 25 years as CEO and Chairman of numerous successful investor-backed software and life-science technology companies, Mr. Connor brings proven company formation, capitalization, operational execution, growth, development, and exit leadership to GenPro. He is a hands-on customer-focused CEO that surrounds himself with outstanding teams aligned to a shared vision.

  • Chief Science Officer and Co-Founder Dr. Marsh is the visionary, inventor and leader of GenPro's core IP and analytics software. He also leads R&D and supports sales and client engagements. A pioneer in the field of computational epigenetics, he invented GenPro's underlying software technology while a faculty member in the Center for Bioinformatics and Computational Biology at the University of Delaware where he is a professor.

  • Chief Commercial Officer Didier leads GenPro's customer-facing functions including business development, sales, marketing and project management. Didier brings to GenPro >25 years of relevant industrial and international biotech/biopharma industry experience and relationships where he served as an executive leader in R&D, project management, GMP manufacturing, and business development with an emphasis in oncology.

  • Chief Technology Officer Mort leads end-to-end development of the GenPro Analytics™ platform. He is responsible for translating Dr.Marsh's research innovations into a secure and scalable platform that operates in a cloud environment to enables customer engagements. A hands-on, business-savvy, developer, innovator and leader, Mort codes, deftly defines architectures, contributes strategically, and drives operational efficiency.

  • Chief Financial Officer

    Andrew is an experienced CFO with a proven record in entrepreneurial start-ups, emerging growth, and Fortune 500 businesses in the US and abroad. He leads finance and administrative functions. He has been a CFO in a number of industries - medical devices, life science, technology, banking, airlines, and education. He is a high-honors MBA from Northeastern University and earned his B.A. in Political Science/Economics from McGill University.


  • Ian Wright
    Tracy Shickel

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free